ScinoPharm and National Health Research Institutes (NHRI) Announce Jointly Developed Diabetes Drug Approved for Phase I Clinical Trial TAIPEI, TAIWAN--(Marketwire - Mar 23, 2012) - ScinoPharm (TWSE1789), a leading active pharmaceutical ingredient (API) and contract research and manufacturing (CRAM) service provider to the global...